Study aim: Determination The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19 Design: Clinical trial with control group, with parallel groups, triple blind, randomized, phase 3 on 88 patients. The randomization will be based on the order of the randomization table prepared by the computer Settings and conduct: This clinical trial will be performed on 88 patients with Covid-19 referring to the clinic of Razi Hospital in Ahvaz. Patients are treated with medication for 4 weeks according to the defined protocol. In order to blind the study, patients, physicians, and researchers are unaware of which group are taking studying drug or placebo. Participants/Inclusion and exclusion criteria: Patients aged 18 to 65 years Laboratory confirmation of Covid-19 (2019-nCoV Real-Time RT-PCR) Intervention groups: Patients in both groups receive the treatment based on the fifth version of the Covid-19 National Guidelines.Patients in the intervention group, in addition to the standard treatment protocol, receive propolis supplement in the form of 500 mg capsules twice a day for 1 month. And the control group also receives placebo according to the above method. Main outcome variables: Cough; Oxygen saturation; Respiratory rate; Body temperature; LI-6; TNF alpha; Crp-hs; CBC